Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Mid-treatment PET scan may allow safer, lower radiation for throat cancer

NCT ID NCT04667585

Disease control Sponsor: Duke University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is testing whether a PET scan taken partway through radiation treatment can identify patients with HPV-related throat cancer who can safely receive a lower dose of radiation. The goal is to reduce side effects while still controlling the cancer. About 120 adults with stage I-III oropharynx cancer are being enrolled.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
reduced dose of radiation therapy
What this could lead to
If successful, this could allow many patients with HPV-related throat cancer to receive less radiation, reducing long-term side effects without compromising cancer control.
What could go wrong
This is a single-arm, non-randomized study with 120 participants, so results may not apply broadly. Lowering radiation might increase the risk of cancer recurrence in some patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 120 people

The number the study aims to enrol. It can still change while the study runs.

Started

Apr 2021

Expected to finish

Jul 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Histologic documentation of squamous cell carcinoma of the oropharynx with p16-positive immunohistochemical staining and/or positive HPV in situ hybridization (ISH) and/or positive HPV PCR * Stage I-III (AJCC 8th edition) with plan for concurrent chemotherapy per standard of care treatment * Zubrod/ECOG score of 0-1 * Weight loss \<10% in the 3 months prior to diagnosis * ≥ 18 years of age * No prior chemotherapy for their current cancer diagnosis Exclusion Criteria: * Prior radiotherapy to the head and neck * Medical contraindications to radiation therapy * Absence of gross disease on imaging prior to beginning radiation therapy * Distant metastatic disease * Medical contraindication to PET/CT * History of active cancer other than non-melanoma skin cancer within the last 5 years

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HPV related oropharyngeal squamous cell carcinoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

human papillomavirus-related squamous cell carcinoma oropharynx cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Oropharynx cancer

Contacts and locations

Locations

  • Duke Raleigh Hospital

    Raleigh, North Carolina, 27609, United States

  • Duke University Medical Center

    Durham, North Carolina, 27710, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.